Preferences for Adult Pneumococcal Vaccine Recommendations Among United States Health Care Providers
| العنوان: | Preferences for Adult Pneumococcal Vaccine Recommendations Among United States Health Care Providers |
|---|---|
| المؤلفون: | Christine Poulos, Vincenza Snow, Jeffrey Vietri, Carolyn Sweeney, Kelley H. Myers, Patricia Sacco, Kelly Hollis |
| المصدر: | Infectious Diseases and Therapy, Vol 8, Iss 4, Pp 657-670 (2019) Infectious Diseases and Therapy |
| بيانات النشر: | Adis, Springer Healthcare, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, Microbiology (medical), Adult, medicine.medical_specialty, Nurse practitioners, Advisory committee, 030106 microbiology, Pneumococcal conjugate vaccine, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, 0302 clinical medicine, Preferences, Health care, medicine, lcsh:RC109-216, 030212 general & internal medicine, Physician assistants, Original Research, business.industry, Pneumococcal vaccine, Disease control, Pneumococcal polysaccharide vaccine, Infectious Diseases, Family medicine, Health care provider, business, medicine.drug |
| الوصف: | Introduction In 2014, the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC) recommended 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all adults aged ≥ 65 years, with a commitment to revisit the recommendation for PCV13 because of declining vaccine-type disease. The Evidence-to-Recommendation framework used by the ACIP includes review of evidence regarding feasibility and stakeholder acceptability, but no surveys of vaccinator preferences have been published in the literature. Methods Physicians (N = 700), physician assistants (N = 100), pharmacists (N = 100), and nurse practitioners (N = 100) who recently prescribed, administered, or recommended adult pneumococcal vaccine were surveyed in March 2018. Object-case best–worst scaling was used to assess preferences among potential recommendation scenarios: retaining the then-current 2014 recommendation without a scheduled re-evaluation, retaining with a scheduled re-evaluation, revising PCV13 to Category B (retaining PPSV23 as Category A), removing PCV13 (retaining PPSV23 as Category A), and removing both PCV13 and PPSV23. Results Providers’ most preferred recommendations were retaining the 2014 recommendation with another planned re-evaluation (52.6%) and retaining the then-current recommendation without planned re-evaluation (40.0%). Few preferred changing PCV13 to Category B (3.2%), removing PCV13 (3.7%), or removing both pneumococcal vaccines (0.5%). Conclusions The majority of vaccinators surveyed preferred to retain the 2014 recommendation, either with another scheduled reassessment or indefinitely. Funding Pfizer, Inc. Electronic Supplementary Material The online version of this article (10.1007/s40121-019-00266-5) contains supplementary material, which is available to authorized users. |
| اللغة: | English |
| تدمد: | 2193-6382 2193-8229 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89dd7a123395e29aa2b76f68e0b874c9 http://link.springer.com/article/10.1007/s40121-019-00266-5 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....89dd7a123395e29aa2b76f68e0b874c9 |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 21936382 21938229 |
|---|